All In Biotech

Drug Trial Radar · NCT07219212

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Jan 26, 2026

Primary completion

Jul 14, 2028

Study completion Jul 14, 2028

Sponsor

Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

  • JNJ-90301900Drug

    JNJ-90301900 will administered via intratumoral and/or intranodal injection.

  • CisplatinDrug

    Cisplatin will be administered intravenously.

  • Intensity Modulated Radiation Therapy (IMRT)Radiation

    IMRT radiation therapy will be administered.

  • CarboplatinDrug

    Carboplatin will be administered intravenously.

  • PaclitaxelDrug

    Paclitaxel will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to approximately 2 years 14 weeks

Locations

25 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • University of California at San Diego Moores Cancer Center

    La Jolla, California · Suspended

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Moffit Cancer center

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Hopital De La Cavale Blanche

    Brest, France · Recruiting

  • CHU de Grenoble

    La Tronche, France · Recruiting

  • Centre Oscar Lambret

    Lille, France · Recruiting

  • Hopital La Timone

    Marseille, France · Recruiting

  • Centre Henri Becquerel

    Rouen, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Hiroshima University Hospital

    Hiroshima, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Japan · Recruiting

  • Aichi Cancer Center

    Nagoya, Japan · Recruiting

  • Shizuoka Cancer Center

    Shizuoka, Japan · Recruiting

  • Tokyo Medical University Hospital

    Tokyo, Japan · Recruiting

  • ICO L'Hospitalet - Hospital Duran i Reynals

    Barcelona, Spain · Recruiting

  • Hosp. Gral. Univ. Gregorio Maranon

    Madrid, Spain · Recruiting

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain · Recruiting

  • Hosp. Univ. I Politecni La Fe

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.